EPRX Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Eupraxia Pharmaceuticals, Inc.'s net margin of 42.95%. Eupraxia Pharmaceuticals, Inc.'s return on equity of -83.44% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Eupraxia Pharmaceuticals, Inc. has a consensus price target of $12.80, signalling upside risk potential of 69.54%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.56%. Given that Eupraxia Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Eupraxia Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Eupraxia Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Eupraxia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eupraxia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Eupraxia Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Eupraxia Pharmaceuticals, Inc.'s net income of -$6.4M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Eupraxia Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eupraxia Pharmaceuticals, Inc. is -- versus 8.63x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edesa Biotech, Inc. has a net margin of -- compared to Eupraxia Pharmaceuticals, Inc.'s net margin of --. Eupraxia Pharmaceuticals, Inc.'s return on equity of -83.44% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Eupraxia Pharmaceuticals, Inc. has a consensus price target of $12.80, signalling upside risk potential of 69.54%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 663.89%. Given that Edesa Biotech, Inc. has higher upside potential than Eupraxia Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Eupraxia Pharmaceuticals, Inc..

Eupraxia Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Eupraxia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eupraxia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Eupraxia Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Eupraxia Pharmaceuticals, Inc.'s net income of -$6.4M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Eupraxia Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eupraxia Pharmaceuticals, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

enGene Holdings, Inc. has a net margin of -- compared to Eupraxia Pharmaceuticals, Inc.'s net margin of --. Eupraxia Pharmaceuticals, Inc.'s return on equity of -83.44% beat enGene Holdings, Inc.'s return on equity of -52.45%.

Eupraxia Pharmaceuticals, Inc. has a consensus price target of $12.80, signalling upside risk potential of 69.54%. On the other hand enGene Holdings, Inc. has an analysts' consensus of $23.50 which suggests that it could grow by 147.37%. Given that enGene Holdings, Inc. has higher upside potential than Eupraxia Pharmaceuticals, Inc., analysts believe enGene Holdings, Inc. is more attractive than Eupraxia Pharmaceuticals, Inc..

Eupraxia Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison enGene Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Eupraxia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enGene Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eupraxia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. enGene Holdings, Inc. pays out -- of its earnings as a dividend.

Eupraxia Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than enGene Holdings, Inc. quarterly revenues of --. Eupraxia Pharmaceuticals, Inc.'s net income of -$6.4M is higher than enGene Holdings, Inc.'s net income of -$37.9M. Notably, Eupraxia Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while enGene Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eupraxia Pharmaceuticals, Inc. is -- versus -- for enGene Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Eupraxia Pharmaceuticals, Inc.'s net margin of --. Eupraxia Pharmaceuticals, Inc.'s return on equity of -83.44% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Eupraxia Pharmaceuticals, Inc. has a consensus price target of $12.80, signalling upside risk potential of 69.54%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 483.09%. Given that Oncolytics Biotech, Inc. has higher upside potential than Eupraxia Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Eupraxia Pharmaceuticals, Inc..

Eupraxia Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Eupraxia Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eupraxia Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Eupraxia Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Eupraxia Pharmaceuticals, Inc.'s net income of -$6.4M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Eupraxia Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eupraxia Pharmaceuticals, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.